CC
ABUS icon

Centiva Capital’s Arbutus Biopharma ABUS Stock Holding History

Centiva Capital’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-187,400
Closed -$483K – 2018
2024
Q1 		$483K Sell
187,400
-562,500
-75% -$1.46M 0.01% 1012
2023
Q4 		$1.87M Buy
+749,900
New +$1.47M 0.04% 375

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

Centiva Capital's ABUS Position: Q1 2025 in Review

Centiva Capital sold out of Arbutus Biopharma (ABUS) in Q1 2025, closing a stake of 30,724 shares — an estimated $100K sold.

Centiva Capital first reported a position in ABUS in Q3 2021 and held it in 9 quarters. The position peaked at $3.55M in Q4 2023. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

  • Centiva Capital reported no remaining Arbutus Biopharma position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 30,724 Arbutus Biopharma shares in Q1 2025, an estimated $100K.
  • Centiva Capital first reported a position in Arbutus Biopharma in Q3 2021 and held it in 9 quarters.
  • Centiva Capital's Arbutus Biopharma position peaked at $3.55M in Q4 2023.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.